← Leaderboards
Louise Hecker
Veterans Health Administration
$1,453,038
Attributed
$2,906,076
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,906,076 · 3
VA$0 · 3
By mechanism
R44$2,045,720 · 1
R21$860,356 · 2
I01$0 · 2
IK2$0 · 1
Top collaborators
- Heidi M. Mansour2 shared
- Joseph Patti2 shared
- Shuichi Takayama2 shared
Most similar at Veterans Health Administration
Same institution · by research overlap
- Venkateshwar G Keshamouni$2,783,665
- Kamal A Mohammed$0
- Hallie Christine Prescott$2,444,964
- Alexander Solomon Rabin$0
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungAgingAge RelatedPathologicPhenotypeCellsIn VivoTissuesResolutionAgedResponseCicatrixMediatingMyofibroblastLung InjuryFibrosisInjuryPre-ClinicalSenescenceExhibitsTherapeutic TargetInsightPathogenesisNadph Oxidase
Grant awards (19)
Advanced Pre-clinical development of Nox4 inhibitors for Pulmonary Fibrosis$1,091,039
R44 · FY2025 · HL
Aging and ARDS: Novel Mechanistic Role of Nox4/D in Age-Dependent Barrier Dysfunction$0
I01 · FY2025 · VA · contact PI
Advanced Pre-clinical development of Nox4 inhibitors for Pulmonary Fibrosis$954,681
R44 · FY2024 · HL
Aging and ARDS: Novel Mechanistic Role of Nox4/D in Age-Dependent Barrier Dysfunction$0
I01 · FY2024 · VA · contact PI
Aging and ARDS: Novel Mechanistic Role of Nox4/D in Age-Dependent Barrier Dysfunction$0
I01 · FY2023 · VA · contact PI
The role of Nampt in age-associated persistent lung fibrosis$0
I01 · FY2022 · VA · contact PI
The role of Nampt in age-associated persistent lung fibrosis$0
I01 · FY2021 · VA · contact PI
3D High Throughput Model to Predict Drug Efficacy in Fibrosis Progression vs Reversal$234,976
R21 · FY2020 · AG
The role of Nampt in age-associated persistent lung fibrosis$0
I01 · FY2020 · VA · contact PI
3D High Throughput Model to Predict Drug Efficacy in Fibrosis Progression vs Reversal$209,890
R21 · FY2019 · AG
The role of Nampt in age-associated persistent lung fibrosis$0
I01 · FY2019 · VA · contact PI
Preclinical development of a novel Nrf2-activator formulation for the treatment of idiopathic pulmonary fibrosis$226,805
R21 · FY2018 · AG · contact PI
The role of Nampt in age-associated persistent lung fibrosis$0
I01 · FY2018 · VA · contact PI
Preclinical development of a novel Nrf2-activator formulation for the treatment of idiopathic pulmonary fibrosis$188,685
R21 · FY2017 · AG · contact PI
Aging, Fibroblast Senescence, and Apoptosis in Lung Fibrosis$0
IK2 · FY2016 · VA · contact PI
Aging, Fibroblast Senescence, and Apoptosis in Lung Fibrosis$0
IK2 · FY2015 · VA · contact PI
Aging, Fibroblast Senescence, and Apoptosis in Lung Fibrosis$0
IK2 · FY2014 · VA · contact PI
Aging, Fibroblast Senescence, and Apoptosis in Lung Fibrosis$0
IK2 · FY2013 · VA · contact PI
Aging, Fibroblast Senescence, and Apoptosis in Lung Fibrosis$0
IK2 · FY2012 · VA · contact PI